Human CD70 Stable Cell Line - CHO-K1

The CD70 gene, also known as CD27LG or TNFSF7, is located on human chromosome 19p13 and encodes a type II transmembrane protein belonging to the tumor necrosis factor superfamily. CD70 is the ligand for the CD27 receptor, and their interaction plays a key role in regulating adaptive immune responses, particularly through costimulatory signaling that drives T cell and B cell activation, proliferation, differentiation, and survival. Under normal physiological conditions, CD70 expression is tightly controlled and transient, appearing primarily on activated T cells, B cells, NK cells, and mature dendritic cells. The Human CD70 Stable Cell Line - CHO-K1 is a recombinant cell line generated by stably transfecting the full-length human CD70 gene into Chinese hamster ovary (CHO-K1) host cells. This engineered cell line consistently expresses human CD70 on the cell surface, providing a reliable and reproducible cell-based platform for a variety of research applications.

This stable cell line is widely used in immunotherapy and oncology drug development. It serves as a critical tool for evaluating the binding affinity and specificity of anti-CD70 monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) targeting CD70-positive tumors. Researchers also employ it as target cells in CAR-T cell functional assays, where the consistent surface expression of CD70 allows for accurate measurement of CAR-T cell-mediated cytotoxicity, activation, and cytokine release. Beyond CAR-T research, the cell line supports CD70-CD27 signaling pathway studies, flow cytometry-based binding assessments, and cell-based screening for small molecule or biologic candidates. Its utility extends to immune checkpoint characterization and combination therapy studies aimed at overcoming tumor immune evasion. The stable and uniform expression of human CD70 in the CHO-K1 background makes this cell line particularly valuable for generating reproducible data across multiple experimental runs, reducing variability and supporting more robust preclinical evaluations.